Ascletis Pharma Inc.
歌禮製藥有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1672)

ANNOUNCEMENT
INSIDE INFORMATION

INCLUSION IN NEW CATALOGUE OF CHINA NATIONAL REIMBURSEMENT DRUG LIST (NRDL) OF ASCLEVIR®/GANOVO® REGIMEN, AN ALL-ORAL DIRECT ANTI-HCV THERAPY AND RESUMPTION OF TRADING

This announcement is made by Ascletis Pharma Inc. (the "**Company**" or "**Ascletis**") pursuant to Rule 13.09(2)(a) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company is pleased to announce that its all-oral direct anti-hepatitis C virus (HCV) ASCLEVIR® (Ravidasvir)/GANOVO® (Danoprevir) regimen has been included in *the Medicine Catalog for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2021) (《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)》)* (the "**National Reimbursement Drug List**" or the "**NRDL**").

The results from the Phase II/III clinical trials in China with the all-oral direct anti-HCV ASCLEVIR®/GANOVO® regimen showed a 99% cure rate in genotype 1 non-cirrhosis HCV patients. ASCLEVIR® is a pan-genotypic NS5A inhibitor with high genetic barrier to resistance, with a cure rate of 100% in patients with baseline NS5A resistance. Both ASCLEVIR® and GANOVO® have been included in *the Guidelines for the Prevention and Treatment of Hepatitis C (2019 version) (《丙型肝炎防治指南(2019版)》) and Management Process of Hospital Screening for Hepatitis C in China (Trial) in 2021 (《中國丙型病毒性肝炎院內篩查管理流程(試行)》)*. Ascletis was the leader for the Anti-HCV Program of National Science and Technology Major Project for "Innovative Drug Development" Programs, and both ASCLEVIR® and GANOVO® are the important achievements of this project during the 13th Five-year Plan Period.

The assessment by National Healthcare Security Administration ("**NHSA**") is based on multi-factors including efficacy, safety, economy, novelty and fairness. The Company is glad that its all-oral regimen has been recognized. There are approximately 10 million patients infected with HCV in China, inclusion in the NRDL will significantly improve the accessibility, release financial burdens of patients and their families, and bring positive impacts to them. The inclusion in NRDL of the all-oral regimen developed by domestic company will further release financial burdens of HCV patients, improve the accessibility of the drugs, eliminate the threat of viral hepatitis to public health and achieve 'Healthy China 2030' objectives.

About Hepatitis C

Hepatitis C is a chronic infection with high morbidity and mortality and is one of the main causes of cirrhosis and liver cancer. There are approximately 10 million people infected with HCV in China with approximately 220,000 new infections each year recently.

RESUMPTION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange was halted with effect from 9:33 a.m. on December 3, 2021 pending the release of this announcement. Application has been made by the Company to the Stock Exchange for the resumption of trading with effect from 1:00 p.m. on December 3, 2021.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hangzhou, the People's Republic of China
December 3, 2021

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.